1
|
Alata W, Yogi A, Brunette E, Delaney CE, Faassen H, Hussack G, Iqbal U, Kemmerich K, Haqqani AS, Moreno MJ, Stanimirovic DB. Targeting insulin‐like growth factor‐1 receptor (IGF1R) for brain delivery of biologics. FASEB J 2022; 36:e22208. [DOI: 10.1096/fj.202101644r] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2021] [Revised: 01/13/2022] [Accepted: 02/01/2022] [Indexed: 12/25/2022]
Affiliation(s)
- Wael Alata
- Human Health Therapeutics Research Centre National Research Council Canada Ottawa Ontario Canada
| | - Alvaro Yogi
- Human Health Therapeutics Research Centre National Research Council Canada Ottawa Ontario Canada
| | - Eric Brunette
- Human Health Therapeutics Research Centre National Research Council Canada Ottawa Ontario Canada
| | - Christie E. Delaney
- Human Health Therapeutics Research Centre National Research Council Canada Ottawa Ontario Canada
| | - Henk Faassen
- Human Health Therapeutics Research Centre National Research Council Canada Ottawa Ontario Canada
| | - Greg Hussack
- Human Health Therapeutics Research Centre National Research Council Canada Ottawa Ontario Canada
| | - Umar Iqbal
- Human Health Therapeutics Research Centre National Research Council Canada Ottawa Ontario Canada
| | - Kristin Kemmerich
- Human Health Therapeutics Research Centre National Research Council Canada Ottawa Ontario Canada
| | - Arsalan S. Haqqani
- Human Health Therapeutics Research Centre National Research Council Canada Ottawa Ontario Canada
| | - Maria J. Moreno
- Human Health Therapeutics Research Centre National Research Council Canada Ottawa Ontario Canada
| | - Danica B. Stanimirovic
- Human Health Therapeutics Research Centre National Research Council Canada Ottawa Ontario Canada
| |
Collapse
|
2
|
Medeiros R, Sousa B, Rossi S, Afonso C, Bonino L, Pitt A, López E, Spickett C, Borthagaray G. Identification and relative quantification of 3-nitrotyrosine residues in fibrinogen nitrated in vitro and fibrinogen from ischemic stroke patient plasma using LC-MS/MS. Free Radic Biol Med 2021; 165:334-347. [PMID: 33548450 DOI: 10.1016/j.freeradbiomed.2021.01.049] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/25/2020] [Revised: 01/25/2021] [Accepted: 01/27/2021] [Indexed: 12/29/2022]
Abstract
Ischemic stroke is one of the leading causes of death and disability worldwide. This acute vascular event interferes with blood supply to the brain and induces a burst of free radicals such as nitric oxide and superoxide, producing peroxynitrite, a precursor of strong nitrating agents. Fibrinogen is one of the most abundant plasma proteins; it plays a role in the hemostatic system, mediating clot formation, which can be affected by nitrotyrosine formation. We hypothesized that nitration of fibrinogen by ONOOH and ONOOCO2- radical products could be one of the early events of the ischemic stroke, and protein-bound 3-nitrotyrosine could be a potential biomarker for diagnosis and/or prognosis of this condition. A targeted mass spectrometry approach was developed to analyze the nitration of fibrinogen and its association with ischemic stroke. First, a comprehensive mapping of 3-nitrotyrosine locations and their relative quantification was performed by LC-MS/MS, using in vitro nitrated fibrinogen samples. Twenty different 3-nitrotyrosine residues were identified on fibrinogen nitrated in vitro, varying with the peroxynitrite tofibrinogen molar ratio used. Nine tyrosine residues that were consistently modified at different treatment ratios were chosen to perform a targeted LC-MS/MS analysis in clinical samples. Enriched fibrinogen fractions from clinical samples from 24 ischemic stroke and 12 patients with non-inflammatory conditions were analysed with this method. Three of the nine tyrosine residues analysed (βY452, βY475 and γY380) showed a significant difference between the ischemic stroke and non-inflammatory disease groups. ROC curve analysis suggested an association of these residues either individually or in combination with ischemic stroke. Different tyrosine nitration patterns were also observed in fibrinogen modified in vitro and in vivo, suggesting differences in the nitration process in these situations. This is the first study showing a putative association between the nitration profile of specific tyrosine residues in human fibrinogen and ischemic stroke.
Collapse
Affiliation(s)
- Romina Medeiros
- Facultad de Química, Universidad de La República, Montevideo, Uruguay.
| | - Bebiana Sousa
- School of Life and Health Sciences, Aston University, Birmingham, UK
| | - Silvina Rossi
- Facultad de Química, Universidad de La República, Montevideo, Uruguay
| | - Catarina Afonso
- School of Life and Health Sciences, Aston University, Birmingham, UK
| | - Luis Bonino
- Facultad de Química, Universidad de La República, Montevideo, Uruguay
| | - Andrew Pitt
- School of Life and Health Sciences, Aston University, Birmingham, UK; Manchester Institute of Biotechnology, University of Manchester, 131 Princess Street, Manchester. M1 7DN, UK
| | - Elizabeth López
- Facultad de Química, Universidad de La República, Montevideo, Uruguay
| | - Corinne Spickett
- School of Life and Health Sciences, Aston University, Birmingham, UK
| | | |
Collapse
|
3
|
Moreno MJ, Ling B, Stanimirovic DB. In vivo near-infrared fluorescent optical imaging for CNS drug discovery. Expert Opin Drug Discov 2020; 15:903-915. [PMID: 32396023 DOI: 10.1080/17460441.2020.1759549] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
INTRODUCTION In vivo imaging technologies have become integral and essential component of drug discovery, development, and clinical assessment for central nervous system (CNS) diseases. Near-infrared (NIR) fluorescence imaging in the range of 650-950 nm is widely used for pre-clinical in vivo imaging studies. The recent expansion of NIR imaging into the shortwave infrared (SWIR, 1000-1700 nm) window enabled improvements in tissue penetration and resolution required for anatomical, dynamic, and molecular neuroimaging with high potential for clinical translation. AREAS COVERED This review focuses on the latest progress in near-infrared (NIR)-fluorescent optical imaging modalities with an emphasis on the SWIR window. Advantages and challenges in developing novel organic and inorganic SWIR emitters, with special attention to their toxicology and pharmacology, are discussed. Examples of their application in preclinical imaging of brain function and pathology provide a platform to assess the potential for their clinical translation. EXPERT OPINION Propelled through concomitant technological advancements in imaging instrumentation, algorithms and new SWIR emitters, SWIR imaging has addressed key barriers to optical imaging modalities used in pre-clinical studies addressing the CNS. Development of biocompatible SWIR emitters and adoption of SWIR into multi-modal imaging modalities promise to rapidly advance optical imaging into translational studies and clinical applications.
Collapse
Affiliation(s)
- Maria J Moreno
- Human Health Therapeutics Research Center, National Research Council Canada , Ottawa, ON, Canada
| | - Binbing Ling
- Human Health Therapeutics Research Center, National Research Council Canada , Ottawa, ON, Canada
| | - Danica B Stanimirovic
- Human Health Therapeutics Research Center, National Research Council Canada , Ottawa, ON, Canada
| |
Collapse
|
4
|
DeGregorio-Rocasolano N, Martí-Sistac O, Gasull T. Deciphering the Iron Side of Stroke: Neurodegeneration at the Crossroads Between Iron Dyshomeostasis, Excitotoxicity, and Ferroptosis. Front Neurosci 2019; 13:85. [PMID: 30837827 PMCID: PMC6389709 DOI: 10.3389/fnins.2019.00085] [Citation(s) in RCA: 92] [Impact Index Per Article: 18.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2018] [Accepted: 01/25/2019] [Indexed: 12/21/2022] Open
Abstract
In general, iron represents a double-edged sword in metabolism in most tissues, especially in the brain. Although the high metabolic demands of brain cells require iron as a redox-active metal for ATP-producing enzymes, the brain is highly vulnerable to the devastating consequences of excessive iron-induced oxidative stress and, as recently found, to ferroptosis as well. The blood-brain barrier (BBB) protects the brain from fluctuations in systemic iron. Under pathological conditions, especially in acute brain pathologies such as stroke, the BBB is disrupted, and iron pools from the blood gain sudden access to the brain parenchyma, which is crucial in mediating stroke-induced neurodegeneration. Each brain cell type reacts with changes in their expression of proteins involved in iron uptake, efflux, storage, and mobilization to preserve its internal iron homeostasis, with specific organelles such as mitochondria showing specialized responses. However, during ischemia, neurons are challenged with excess extracellular glutamate in the presence of high levels of extracellular iron; this causes glutamate receptor overactivation that boosts neuronal iron uptake and a subsequent overproduction of membrane peroxides. This glutamate-driven neuronal death can be attenuated by iron-chelating compounds or free radical scavenger molecules. Moreover, vascular wall rupture in hemorrhagic stroke results in the accumulation and lysis of iron-rich red blood cells at the brain parenchyma and the subsequent presence of hemoglobin and heme iron at the extracellular milieu, thereby contributing to iron-induced lipid peroxidation and cell death. This review summarizes recent progresses made in understanding the ferroptosis component underlying both ischemic and hemorrhagic stroke subtypes.
Collapse
Affiliation(s)
- Núria DeGregorio-Rocasolano
- Cellular and Molecular Neurobiology Research Group, Department of Neurosciences, Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain
| | - Octavi Martí-Sistac
- Cellular and Molecular Neurobiology Research Group, Department of Neurosciences, Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.,Department of Cellular Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, Bellaterra, Spain
| | - Teresa Gasull
- Cellular and Molecular Neurobiology Research Group, Department of Neurosciences, Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain
| |
Collapse
|
5
|
Liang X, Shang W, Chi C, Zeng C, Wang K, Fang C, Chen Q, Liu H, Fan Y, Tian J. Dye-conjugated single-walled carbon nanotubes induce photothermal therapy under the guidance of near-infrared imaging. Cancer Lett 2016; 383:243-249. [DOI: 10.1016/j.canlet.2016.09.006] [Citation(s) in RCA: 58] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2016] [Revised: 09/01/2016] [Accepted: 09/02/2016] [Indexed: 01/21/2023]
|
6
|
Subdural hematoma decompression model: A model of traumatic brain injury with ischemic-reperfusional pathophysiology: A review of the literature. Behav Brain Res 2016; 340:23-28. [PMID: 27235716 DOI: 10.1016/j.bbr.2016.05.055] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2016] [Revised: 05/20/2016] [Accepted: 05/24/2016] [Indexed: 11/23/2022]
Abstract
The prognosis for patients with traumatic brain injury (TBI) with subdural hematoma (SDH) remains poor. In accordance with an increasing elderly population, the incidence of geriatric TBI with SDH is rising. An important contributor to the neurological injury associated with SDH is the ischemic damage which is caused by raised intracranial pressure (ICP) producing impaired cerebral perfusion. To control intracranial hypertension, the current management consists of hematoma evacuation with or without decompressive craniotomy. This removal of the SDH results in the immediate reversal of global ischemia accompanied by an abrupt reduction of mass lesion and an ensuing reperfusion injury. Experimental models can play a critical role in improving our understanding of the underlying pathophysiology and in exploring potential treatments for patients with SDH. In this review, we describe the epidemiology, pathophysiology and clinical background of SDH.
Collapse
|
7
|
Poinsatte K, Selvaraj UM, Ortega SB, Plautz EJ, Kong X, Gidday JM, Stowe AM. Quantification of neurovascular protection following repetitive hypoxic preconditioning and transient middle cerebral artery occlusion in mice. J Vis Exp 2015:e52675. [PMID: 25993394 DOI: 10.3791/52675] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Experimental animal models of stroke are invaluable tools for understanding stroke pathology and developing more effective treatment strategies. A 2 week protocol for repetitive hypoxic preconditioning (RHP) induces long-term protection against central nervous system (CNS) injury in a mouse model of focal ischemic stroke. RHP consists of 9 stochastic exposures to hypoxia that vary in both duration (2 or 4 hr) and intensity (8% and 11% O2). RHP reduces infarct volumes, blood-brain barrier (BBB) disruption, and the post-stroke inflammatory response for weeks following the last exposure to hypoxia, suggesting a long-term induction of an endogenous CNS-protective phenotype. The methodology for the dual quantification of infarct volume and BBB disruption is effective in assessing neurovascular protection in mice with RHP or other putative neuroprotectants. Adult male Swiss Webster mice were preconditioned by RHP or duration-equivalent exposures to 21% O2 (i.e. room air). A 60 min transient middle cerebral artery occlusion (tMCAo) was induced 2 weeks following the last hypoxic exposure. Both the occlusion and reperfusion were confirmed by transcranial laser Doppler flowmetry. Twenty-two hr after reperfusion, Evans Blue (EB) was intravenously administered through a tail vein injection. 2 hr later, animals were sacrificed by isoflurane overdose and brain sections were stained with 2,3,5- triphenyltetrazolium chloride (TTC). Infarcts volumes were then quantified. Next, EB was extracted from the tissue over 48 hr to determine BBB disruption after tMCAo. In summary, RHP is a simple protocol that can be replicated, with minimal cost, to induce long-term endogenous neurovascular protection from stroke injury in mice, with the translational potential for other CNS-based and systemic pro-inflammatory disease states.
Collapse
Affiliation(s)
- Katherine Poinsatte
- Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center
| | - Uma Maheswari Selvaraj
- Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center
| | - Sterling B Ortega
- Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center
| | - Erik J Plautz
- Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center
| | - Xiangmei Kong
- Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center
| | - Jeffrey M Gidday
- Department of Neurological Surgery, Washington University School of Medicine
| | - Ann M Stowe
- Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center;
| |
Collapse
|
8
|
Image-Guided Delivery of Therapeutics to the Brain. ADVANCES IN DELIVERY SCIENCE AND TECHNOLOGY 2015. [DOI: 10.1007/978-3-319-11355-5_4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
9
|
Ill-Raga G, Palomer E, Ramos-Fernández E, Guix FX, Bosch-Morató M, Guivernau B, Tajes M, Valls-Comamala V, Jiménez-Conde J, Ois A, Pérez-Asensio F, Reyes-Navarro M, Caballo C, Gil-Gómez G, Lopez-Vilchez I, Galan AM, Alameda F, Escolar G, Opazo C, Planas AM, Roquer J, Valverde MA, Muñoz FJ. Fibrinogen nitrotyrosination after ischemic stroke impairs thrombolysis and promotes neuronal death. Biochim Biophys Acta Mol Basis Dis 2014; 1852:421-8. [PMID: 25500153 DOI: 10.1016/j.bbadis.2014.12.007] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2014] [Revised: 11/11/2014] [Accepted: 12/05/2014] [Indexed: 10/24/2022]
Abstract
Ischemic stroke is an acute vascular event that compromises neuronal viability, and identification of the pathophysiological mechanisms is critical for its correct management. Ischemia produces increased nitric oxide synthesis to recover blood flow but also induces a free radical burst. Nitric oxide and superoxide anion react to generate peroxynitrite that nitrates tyrosines. We found that fibrinogen nitrotyrosination was detected in plasma after the initiation of ischemic stroke in human patients. Electron microscopy and protein intrinsic fluorescence showed that in vitro nitrotyrosination of fibrinogen affected its structure. Thromboelastography showed that initially fibrinogen nitrotyrosination retarded clot formation but later made the clot more resistant to fibrinolysis. This result was independent of any effect on thrombin production. Immunofluorescence analysis of affected human brain areas also showed that both fibrinogen and nitrotyrosinated fibrinogen spread into the brain parenchyma after ischemic stroke. Therefore, we assayed the toxicity of fibrinogen and nitrotyrosinated fibrinogen in a human neuroblastoma cell line. For that purpose we measured the activity of caspase-3, a key enzyme in the apoptotic pathway, and cell survival. We found that nitrotyrosinated fibrinogen induced higher activation of caspase 3. Accordingly, cell survival assays showed a more neurotoxic effect of nitrotyrosinated fibrinogen at all concentrations tested. In summary, nitrotyrosinated fibrinogen would be of pathophysiological interest in ischemic stroke due to both its impact on hemostasis - it impairs thrombolysis, the main target in stroke treatments - and its neurotoxicity that would contribute to the death of the brain tissue surrounding the infarcted area.
Collapse
Affiliation(s)
- Gerard Ill-Raga
- Laboratory of Molecular Physiology and Channelopathies, Universitat Pompeu Fabra, Barcelona, Catalonia 08003, Spain
| | - Ernest Palomer
- Laboratory of Molecular Physiology and Channelopathies, Universitat Pompeu Fabra, Barcelona, Catalonia 08003, Spain
| | - Eva Ramos-Fernández
- Laboratory of Molecular Physiology and Channelopathies, Universitat Pompeu Fabra, Barcelona, Catalonia 08003, Spain
| | - Francesc X Guix
- Laboratory of Molecular Physiology and Channelopathies, Universitat Pompeu Fabra, Barcelona, Catalonia 08003, Spain
| | - Mònica Bosch-Morató
- Laboratory of Molecular Physiology and Channelopathies, Universitat Pompeu Fabra, Barcelona, Catalonia 08003, Spain
| | - Biuse Guivernau
- Laboratory of Molecular Physiology and Channelopathies, Universitat Pompeu Fabra, Barcelona, Catalonia 08003, Spain
| | - Marta Tajes
- Laboratory of Molecular Physiology and Channelopathies, Universitat Pompeu Fabra, Barcelona, Catalonia 08003, Spain
| | - Victòria Valls-Comamala
- Laboratory of Molecular Physiology and Channelopathies, Universitat Pompeu Fabra, Barcelona, Catalonia 08003, Spain
| | - Jordi Jiménez-Conde
- Servei de Neurologia, Hospital del Mar-IMIM-Parc de Salut Mar, Barcelona, Catalonia 08003, Spain
| | - Angel Ois
- Servei de Neurologia, Hospital del Mar-IMIM-Parc de Salut Mar, Barcelona, Catalonia 08003, Spain
| | - Fernando Pérez-Asensio
- Institut d'Investigacions Biomèdiques de Barcelona (IIBB)-Consejo Superior de Investigaciones Científicas (CSIC), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia 08036, Spain
| | - Mario Reyes-Navarro
- Laboratory of Neurobiometals, Department of Physiology, University of Concepción, 4089100, Chile
| | - Carolina Caballo
- Department of Hemotherapy and Hemostasis, Hospital Clinic, Biomedical Diagnosis Centre, Institute of Biomedical Research August Pi i Sunyer, University of Barcelona, Catalonia 08036, Spain
| | - Gabriel Gil-Gómez
- Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Parc de Salut Mar, Barcelona, Catalonia 08003, Spain
| | - Irene Lopez-Vilchez
- Department of Hemotherapy and Hemostasis, Hospital Clinic, Biomedical Diagnosis Centre, Institute of Biomedical Research August Pi i Sunyer, University of Barcelona, Catalonia 08036, Spain
| | - Ana M Galan
- Department of Hemotherapy and Hemostasis, Hospital Clinic, Biomedical Diagnosis Centre, Institute of Biomedical Research August Pi i Sunyer, University of Barcelona, Catalonia 08036, Spain
| | - Francesc Alameda
- Servei d'Anatomia Patològica, Hospital del Mar-IMIM-Parc de Salut Mar, Barcelona, Catalonia 08003, Spain
| | - Gines Escolar
- Department of Hemotherapy and Hemostasis, Hospital Clinic, Biomedical Diagnosis Centre, Institute of Biomedical Research August Pi i Sunyer, University of Barcelona, Catalonia 08036, Spain
| | - Carlos Opazo
- Laboratory of Neurobiometals, Department of Physiology, University of Concepción, 4089100, Chile; Oxidation Biology Laboratory, The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, 3010, Australia
| | - Anna M Planas
- Institut d'Investigacions Biomèdiques de Barcelona (IIBB)-Consejo Superior de Investigaciones Científicas (CSIC), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia 08036, Spain
| | - Jaume Roquer
- Servei de Neurologia, Hospital del Mar-IMIM-Parc de Salut Mar, Barcelona, Catalonia 08003, Spain
| | - Miguel A Valverde
- Laboratory of Molecular Physiology and Channelopathies, Universitat Pompeu Fabra, Barcelona, Catalonia 08003, Spain
| | - Francisco J Muñoz
- Laboratory of Molecular Physiology and Channelopathies, Universitat Pompeu Fabra, Barcelona, Catalonia 08003, Spain.
| |
Collapse
|
10
|
Zheng S, Bai YY, Changyi Y, Gao X, Zhang W, Wang Y, Zhou L, Ju S, Li C. Multimodal nanoprobes evaluating physiological pore size of brain vasculatures in ischemic stroke models. Adv Healthc Mater 2014; 3:1909-18. [PMID: 24898608 DOI: 10.1002/adhm.201400159] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2014] [Revised: 04/29/2014] [Indexed: 12/25/2022]
Abstract
Ischemic stroke accounts for 80% strokes and originates from a reduction of cerebral blood flow (CBF) after vascular occlusion. For treatment, the first action is to restore CBF by thrombolytic agent recombinant tissue-type plasminogen activator (rt-PA). Although rt-PA benefits clinical outcome, its application is limited by short therapeutic time window and risk of brain hemorrhage. Different to thrombolytic agents, neuroprotectants reduce neurological injuries by blocking ischemic cascade events such as excitotoxicity and oxidative stress. Nano-neuroprotectants demonstrate higher therapeutic effect than small molecular analogues due to their prolonged circulation lifetime and disrupted blood-brain barrier (BBB) in ischemic region. Even enhanced BBB permeability in ischemic territories is verified, the pore size of ischemic vasculatures determining how large and how efficient the therapeutics can pass is barely studied. In this work, nanoprobes (NPs) with different diameters are developed. In vivo multimodal imaging indicates that NP uptakes in ischemic region depended on their diameters and the pore size upper limit of ischemic vasculatures is determined as 10-11 nm. Additionally, penumbra defined as salvageable ischemic tissues performed a higher BBB permeability than infarct core. This work provides a guideline for developing nano-neuroprotectants by taking advantage of the locally enhanced BBB permeability in ischemic brain tissues.
Collapse
Affiliation(s)
- Shuyan Zheng
- Key Laboratory of Smart Drug Delivery Ministry of Education; School of Pharmacy Fudan University; Shanghai 201203 China
| | - Ying-Ying Bai
- Jiangsu Key Laboratory of Molecular and Functional Imaging, Department of Radiology; Zhongda Hospital Medical School of Southeast University; Nanjing 210009 China
| | - Yinzhi Changyi
- Key Laboratory of Smart Drug Delivery Ministry of Education; School of Pharmacy Fudan University; Shanghai 201203 China
| | - Xihui Gao
- Key Laboratory of Smart Drug Delivery Ministry of Education; School of Pharmacy Fudan University; Shanghai 201203 China
| | - Wenqing Zhang
- Key Laboratory of Smart Drug Delivery Ministry of Education; School of Pharmacy Fudan University; Shanghai 201203 China
| | - Yuancheng Wang
- Jiangsu Key Laboratory of Molecular and Functional Imaging, Department of Radiology; Zhongda Hospital Medical School of Southeast University; Nanjing 210009 China
| | - Lu Zhou
- Key Laboratory of Smart Drug Delivery Ministry of Education; School of Pharmacy Fudan University; Shanghai 201203 China
| | - Shenghong Ju
- Jiangsu Key Laboratory of Molecular and Functional Imaging, Department of Radiology; Zhongda Hospital Medical School of Southeast University; Nanjing 210009 China
| | - Cong Li
- Key Laboratory of Smart Drug Delivery Ministry of Education; School of Pharmacy Fudan University; Shanghai 201203 China
| |
Collapse
|
11
|
Warram JM, Sorace AG, Mahoney M, Samuel S, Harbin B, Joshi M, Martin A, Whitworth L, Hoyt K, Zinn KR. Biodistribution of P-selectin targeted microbubbles. J Drug Target 2014; 22:387-94. [PMID: 24731055 DOI: 10.3109/1061186x.2013.869822] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
PURPOSE To evaluate binding of P-selectin targeted microbubbles (MB) in tumor vasculature; a whole-body imaging and biodistribution study was performed in a tumor bearing mouse model. METHODS Antibodies were radiolabeled with Tc-99 m using the HYNIC method. Tc-99 m labeled anti-P-selectin antibodies were avidin-bound to lipid-shelled, perfluorocarbon gas-filled MB and intravenously injected into mice bearing MDA-MB-231 breast tumors. Whole-body biodistribution was performed at 5 min (n = 12) and 60 min (n = 4) using a gamma counter. Tc-99 m-labeled IgG bound IgG-control-MB group (n = 12 at 5 min; n = 4 at 60 min), Tc-99 m-labeled IgG-control-Ab group (n = 5 at 5 min; n = 3 at 60 min) and Tc-99 m-labeled anti P-selectin-Ab group (n = 5 at 5 min; n = 3 at 60 min) were also evaluated. Planar gamma camera imaging was also performed at each time point. RESULTS Targeted-MB retention in tumor (60 min: 1.8 ± 0.3% ID/g) was significantly greater (p = 0.01) than targeted-MB levels in adjacent skeletal muscle at both time points (5 min: 0.7 ± 0.2% ID/g; 60 min: 0.2 ± 0.1% ID/g) while there was no significant difference (p = 0.17) between muscle and tumor retention for the IgG-control-MB group at 5 min. CONCLUSIONS P-selectin targeted MBs were significantly higher in tumor tissue, as compared with adjacent skeletal tissue or tumor retention of IgG-control-MB.
Collapse
|
12
|
Jiang S, Xia R, Jiang Y, Wang L, Gao F. Vascular endothelial growth factors enhance the permeability of the mouse blood-brain barrier. PLoS One 2014; 9:e86407. [PMID: 24551038 PMCID: PMC3925082 DOI: 10.1371/journal.pone.0086407] [Citation(s) in RCA: 68] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2013] [Accepted: 12/11/2013] [Indexed: 02/05/2023] Open
Abstract
The blood-brain barrier (BBB) impedes entry of many drugs into the brain, limiting clinical efficacy. A safe and efficient method for reversibly increasing BBB permeability would greatly facilitate central nervous system (CNS) drug delivery and expand the range of possible therapeutics to include water soluble compounds, proteins, nucleotides, and other large molecules. We examined the effect of vascular endothelial growth factor (VEGF) on BBB permeability in Kunming (KM) mice. Human VEGF165 was administered to treatment groups at two concentrations (1.6 or 3.0 µg/mouse), while controls received equal-volume saline. Changes in BBB permeability were measured by parenchymal accumulation of the contrast agent Gd-DTPA as assessed by 7 T magnetic resonance imaging (MRI). Mice were then injected with Evans blue, sacrificed 0.5 h later, and perfused transcardially. Brains were removed, fixed, and sectioned for histological study. Both VEGF groups exhibited a significantly greater signal intensity from the cerebral cortex and basal ganglia than controls (P<0.001). Evans blue fluorescence intensity was higher in the parenchyma and lower in the cerebrovasculature of VEGF-treated animals compared to controls. No significant brain edema was observed by diffusion weighted MRI (DWI) or histological staining. Exogenous application of VEGF can increase the permeability of the BBB without causing brain edema. Pretreatment with VEGF may be a feasible method to facilitate drug delivery into the CNS.
Collapse
Affiliation(s)
- Shize Jiang
- Molecular Imaging Laboratory, Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China, People’s Republic of
| | - Rui Xia
- Molecular Imaging Laboratory, Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China, People’s Republic of
| | - Yong Jiang
- Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China, People’s Republic of
| | - Lei Wang
- Molecular Imaging Laboratory, Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China, People’s Republic of
| | - Fabao Gao
- Molecular Imaging Laboratory, Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China, People’s Republic of
- * E-mail:
| |
Collapse
|
13
|
Regenhardt RW, Bennion DM, Sumners C. Cerebroprotective action of angiotensin peptides in stroke. Clin Sci (Lond) 2014; 126:195-205. [PMID: 24102099 PMCID: PMC7453725 DOI: 10.1042/cs20130324] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The goal of the present review is to examine the evidence for beneficial actions of manipulation of the RAS (renin-angiotensin system) in stroke, with particular focus on Ang-(1-7) [angiotensin-(1-7)] and its receptor Mas. The RAS appears to be highly involved in the multifactorial pathophysiology of stroke. Blocking the effects of AngII (angiotensin II) at AT1R (AngII type 1 receptor), through the use of commonly prescribed ACE (angiotensin-converting enzyme) inhibitors or AT1R blockers, has been shown to have therapeutic effects in both ischaemic and haemorrhagic stroke. In contrast with the deleterious actions of over activation of AT1R by AngII, stimulation of AT2Rs (AngII type 2 receptors) in the brain has been demonstrated to elicit beneficial effects in stroke. Likewise, the ACE2/Ang-(1-7)/Mas axis of the RAS has been shown to have therapeutic effects in stroke when activated, countering the effects of the ACE/AngII/AT1R axis. Studies have demonstrated that activating this axis in the brain elicits beneficial cerebral effects in rat models of ischaemic stroke, and we have also demonstrated the cerebroprotective potential of this axis in haemorrhagic stroke using stroke-prone spontaneously hypertensive rats and collagenase-induced striatal haemorrhage. The mechanism of cerebroprotection elicited by ACE2/Ang-(1-7)/Mas activation includes anti-inflammatory effects within the brain parenchyma. The major hurdle to overcome in translating these results to humans is devising strategies to activate the ACE2/Ang-(1-7)/Mas cerebroprotective axis using post-stroke treatments that can be administered non-invasively.
Collapse
Affiliation(s)
- Robert W. Regenhardt
- Department of Physiology and Functional Genomics & McKnight Brain Institute, University of Florida, 1600 SW Archer Road, PO Box 100274, Gainesville, FL 32610-0274, USA
| | - Douglas M. Bennion
- Department of Physiology and Functional Genomics & McKnight Brain Institute, University of Florida, 1600 SW Archer Road, PO Box 100274, Gainesville, FL 32610-0274, USA
| | - Colin Sumners
- Department of Physiology and Functional Genomics & McKnight Brain Institute, University of Florida, 1600 SW Archer Road, PO Box 100274, Gainesville, FL 32610-0274, USA
| |
Collapse
|
14
|
Zhang W, Xiong H, Callaghan D, Liu H, Jones A, Pei K, Fatehi D, Brunette E, Stanimirovic D. Blood-brain barrier transport of amyloid beta peptides in efflux pump knock-out animals evaluated by in vivo optical imaging. Fluids Barriers CNS 2013; 10:13. [PMID: 23432917 PMCID: PMC3601014 DOI: 10.1186/2045-8118-10-13] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2012] [Accepted: 02/22/2013] [Indexed: 12/28/2022] Open
Abstract
Background Aβ transport (flux) across the blood-brain barrier (BBB) is thought to contribute to the pathogenesis of Alzheimer’s disease as well as to elimination of toxic amyloid from the brain by immunotherapy. Several BBB transporters have been implicated in Aβ exchange between brain parenchyma and the circulation, including efflux transporters P-glycoprotein/ABCB1 and BCRP/ABCG2. Here we describe an application of in vivo optical imaging methods to study Aβ transport across the BBB in wild-type or animals deficient in specific efflux transporters. Methods/Design Synthetic human Aβ1-40 or scrambled Aβ40-1 peptides were labeled with the near-infrared fluorescent tracer, Cy5.5. The free tracer or Cy5.5-labeled peptides were injected intravenously into Abcb1-KO or Abcg2-KO mice or their corresponding wild-type controls. The animals were imaged prospectively at different time points over a period of 8 hours using eXplore Optix small animal imager. At the end of the observation, animals were sacrificed by perfusion, their brains were imaged ex-vivo and sectioned for immunofluorescence analyses. Discussion After appropriate circulation time, the fluorescence concentration in the head ROI measured in vivo was close to background values in both wild-type and Abcb1-KO or Abcg2-KO mice injected with either free dye or scrambled Aβ40-1-Cy5.5. In animals injected with Aβ1-40-Cy5.5, the deficiency in either Abcb1 or Abcg2 resulted in significant increases in fluorescence concentration in the head ROIs 2 hours after injection compared to wild-type animals. Fluorescence decay (elimination rate) over 2–8 hours after injection was similar between wild-type (t1/2 = 1.97 h) and Abcg2-KO (t1/2 = 2.34 h) and was slightly faster (t1/2 = 1.38 h) in Abcb1-KO mice. In vivo time-domain imaging method allows prospective, dynamic analyses of brain uptake/elimination of fluorescently-labeled compounds, including Aβ. Deficiency of either of the two major efflux pumps, Abcb1 and Abcg2, implicated in Aβ trafficking across the BBB, resulted in increased accumulation of peripherally-injected Aβ1-40 in the brain.
Collapse
Affiliation(s)
- Wandong Zhang
- Human Health & Therapeutics Portfolio, National Research Council of Canada, Ottawa, Canada.
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Sorace AG, Saini R, Rosenthal E, Warram JM, Zinn KR, Hoyt K. Optical fluorescent imaging to monitor temporal effects of microbubble-mediated ultrasound therapy. IEEE TRANSACTIONS ON ULTRASONICS, FERROELECTRICS, AND FREQUENCY CONTROL 2013; 60:281-9. [PMID: 23357902 PMCID: PMC3628607 DOI: 10.1109/tuffc.2013.2564] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
Microbubble-mediated ultrasound therapy can noninvasively enhance drug delivery to localized regions in the body. This technique can be beneficial in cancer therapy, but currently there are limitations to tracking the therapeutic effects. The purpose of this experiment was to investigate the potential of fluorescent imaging for monitoring the temporal effects of microbubble-mediated ultrasound therapy. Mice were implanted with 2LMP breast cancer cells. The animals underwent microbubble-mediated ultrasound therapy in the presence of Cy5.5 fluorescent-labeled IgG antibody (large molecule) or Cy5.5 dye (small molecule) and microbubble contrast agents. Control animals were administered fluorescent molecules only. Animals were transiently imaged in vivo at 1, 10, 30, and 60 min post therapy using a small animal optical imaging system. Tumors were excised and analyzed ex vivo. Tumors were homogenized and emulsion imaged for Cy5.5 fluorescence. Monitoring in vivo results showed significant influx of dye into the tumor (p < 0.05) using the small molecule, but not in the large molecule group (p > 0.05). However, after tumor emulsion, significantly higher dye concentration was detected in therapy group tumors for both small and large molecule groups in comparison to their control counterparts (p <0.01). This paper explores a noninvasive optical imaging method for monitoring the effects of microbubble-mediated ultrasound therapy in a cancer model. It provides temporal information following the process of increasing extravasation of molecules into target tumors.
Collapse
Affiliation(s)
- Anna G. Sorace
- Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL
| | - Reshu Saini
- Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL
| | - Eben Rosenthal
- Department of Surgery, University of Alabama at Birmingham, Birmingham, AL
| | - Jason M. Warram
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL
| | - Kurt R. Zinn
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL. Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL
| | - Kenneth Hoyt
- Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL. Department of Radiology, University of Alabama at Birmingham, Birmingham, AL. Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL
| |
Collapse
|
16
|
Yokobori S, Frantzen J, Bullock R, Gajavelli S, Burks S, Bramlett H, Dietrich WD. The Use of Hypothermia Therapy in Traumatic Ischemic / Reperfusional Brain Injury: Review of the Literatures. Ther Hypothermia Temp Manag 2011; 1:185-192. [PMID: 23439678 PMCID: PMC3579497 DOI: 10.1089/ther.2011.0012] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Therapeutic mild hypothermia has been used widely in brain injury. It has evaluated in numerous clinical trials, and there is strong evidence for the use of hypothermia in treating patients with several types of ischemic / reperfusional (I/R) injuries, examples being cardiac arrest and neonatal hypoxic-ischemic encephalopathy.In spite of many basic research projects demonstrating effectiveness, therapeutic hypothermia has not been proven effective for the heterogeneous group of traumatic brain injury patients in multicenter clinical trials. In the latest clinical trial, however, researchers were able to demonstrate the significant beneficial effects of hypothermia in one specific group; patients with mass evacuated lesions. This suggested that mild therapeutic hypothermia might be effective for I/R related traumatic brain injury.In this article we have reviewed much of the previous literature concerning the mechanisms of I/R injury to the protective effects of mild therapeutic hypothermia.
Collapse
Affiliation(s)
- Shoji Yokobori
- Department of Neurosurgery, The Miami Project to Cure Paralysis University of Miami Miller school of Medicine, Miami, Florida
| | | | | | | | | | | | | |
Collapse
|